Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISAL 2023 | Using a genome-wide CRISPR screen to evaluate mechanisms of resistance to FLT3 inhibitors in AML

Jian Huang • 20 Mar 2023
ISAL 2023
Acute Myeloid Leukemia Leukemia

Jian Huang, MD, PhD, Coriell Institute for Medical Research, Camden, NJ, shares some insights into a study which used genome-wide CRISPR screening to investigate the molecular mechanisms underlying resistance to FLT3 inhibitors in acute myeloid leukemia (AML). This interview took place at the 18th International Symposium on Acute Leukemias (ISAL XVIII), held in Munich, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals